States with high concentrations of vulnerable populations, eg, older, sicker, but also poorer with basic needs unmet, face challenges as the COVID-19 lock-down lifts.
FDA Grants Full Approval of Moderna’s COVID-19 Vaccine for High-Risk Children Aged 6 Months to 11 Years
Moderna’s Spikevax receives full FDA approval for use in children at increased risk for COVID-19, expanding protection ahead of the 2025–2026 virus season.
Respiratory Tripledemic 2022-23: An Expert Recap
William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.
Intranasal COVID-19 Vaccine Found Safe and Immunogenic in Open Label Phase 1 Clinical Trial
Among recipients of high-dose CVXGA, relative vaccine effectiveness was 67.8% against symptomatic COVID infection at a median 7.3 months post-vaccination.
Cold & Flu Season 2022-23: AAFP Board Chair Shares Concerns
"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with American Academy of Family Physicians Board Chair Sterling Ransone, Jr, MD.
Kennedy's First Pass at US Vaccine Policy: ACIP Guidance Reversed, Clinical Trials Amended, WHO Abandoned
Kennedy over 2 weeks has introduced changes in vaccination recommendations and research policy that undermine already tenuous public trust and understanding.
FDA Advisory Panel Recommends Continued Use of Monovalent JN.1 Strain for COVID-19 Vaccines
FDA panel endorses continued use of monovalent JN.1 strain for COVID-19 vaccines, aligning with global health recommendations amid evolving variants.